MLAB Quote, Financials, Valuation and Earnings

Focus Universal has a net margin of -2.67% compared to Mesa Laboratories's net margin of -657.74%. Mesa Laboratories's return on equity of -122.79% beat Focus Universal's return on equity of -111.52%.

Mesa Laboratories has a consensus price target of $141.67, signalling upside risk potential of 11.6%. On the other hand Focus Universal has an analysts' consensus of -- which suggests that it could fall by --. Given that Mesa Laboratories has higher upside potential than Focus Universal, analysts believe Mesa Laboratories is more attractive than Focus Universal.

Mesa Laboratories has a beta of 0.966, which suggesting that the stock is 3.358% less volatile than S&P 500. In comparison Focus Universal has a beta of 0.261, suggesting its less volatile than the S&P 500 by 73.875%.

Mesa Laboratories has a quarterly dividend of $0.16 per share corresponding to a yield of 0.5%. Focus Universal offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesa Laboratories pays -1.36% of its earnings as a dividend. Focus Universal pays out -- of its earnings as a dividend.

Mesa Laboratories quarterly revenues are $62.8M, which are larger than Focus Universal quarterly revenues of $190.3K. Mesa Laboratories's net income of -$1.7M is lower than Focus Universal's net income of -$1.3M. Notably, Mesa Laboratories's price-to-earnings ratio is -- while Focus Universal's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesa Laboratories is 2.90x versus 77.63x for Focus Universal. Usually stocks with elevated PS ratios are considered overvalued.

Keysight Technologies has a net margin of -2.67% compared to Mesa Laboratories's net margin of 13.02%. Mesa Laboratories's return on equity of -122.79% beat Keysight Technologies's return on equity of 12.1%.

Mesa Laboratories has a consensus price target of $141.67, signalling upside risk potential of 11.6%. On the other hand Keysight Technologies has an analysts' consensus of $179.01 which suggests that it could grow by 8.45%. Given that Mesa Laboratories has higher upside potential than Keysight Technologies, analysts believe Mesa Laboratories is more attractive than Keysight Technologies.

Mesa Laboratories has a beta of 0.966, which suggesting that the stock is 3.358% less volatile than S&P 500. In comparison Keysight Technologies has a beta of 1.104, suggesting its more volatile than the S&P 500 by 10.426%.

Mesa Laboratories has a quarterly dividend of $0.16 per share corresponding to a yield of 0.5%. Keysight Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesa Laboratories pays -1.36% of its earnings as a dividend. Keysight Technologies pays out -- of its earnings as a dividend.

Mesa Laboratories quarterly revenues are $62.8M, which are smaller than Keysight Technologies quarterly revenues of $1.3B. Mesa Laboratories's net income of -$1.7M is lower than Keysight Technologies's net income of $169M. Notably, Mesa Laboratories's price-to-earnings ratio is -- while Keysight Technologies's PE ratio is 47.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesa Laboratories is 2.90x versus 5.75x for Keysight Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Qorvo has a net margin of -2.67% compared to Mesa Laboratories's net margin of 3.61%. Mesa Laboratories's return on equity of -122.79% beat Qorvo's return on equity of 1.61%.

Mesa Laboratories has a consensus price target of $141.67, signalling upside risk potential of 11.6%. On the other hand Qorvo has an analysts' consensus of $82.98 which suggests that it could grow by 5.6%. Given that Mesa Laboratories has higher upside potential than Qorvo, analysts believe Mesa Laboratories is more attractive than Qorvo.

Mesa Laboratories has a beta of 0.966, which suggesting that the stock is 3.358% less volatile than S&P 500. In comparison Qorvo has a beta of 1.381, suggesting its more volatile than the S&P 500 by 38.058%.

Mesa Laboratories has a quarterly dividend of $0.16 per share corresponding to a yield of 0.5%. Qorvo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesa Laboratories pays -1.36% of its earnings as a dividend. Qorvo pays out -- of its earnings as a dividend.

Mesa Laboratories quarterly revenues are $62.8M, which are smaller than Qorvo quarterly revenues of $869.5M. Mesa Laboratories's net income of -$1.7M is lower than Qorvo's net income of $31.4M. Notably, Mesa Laboratories's price-to-earnings ratio is -- while Qorvo's PE ratio is 134.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesa Laboratories is 2.90x versus 2.01x for Qorvo. Usually stocks with elevated PS ratios are considered overvalued.

Sono-Tek has a net margin of -2.67% compared to Mesa Laboratories's net margin of 5.28%. Mesa Laboratories's return on equity of -122.79% beat Sono-Tek's return on equity of 6.6%.

Mesa Laboratories has a consensus price target of $141.67, signalling upside risk potential of 11.6%. On the other hand Sono-Tek has an analysts' consensus of $8.25 which suggests that it could grow by 109.39%. Given that Sono-Tek has higher upside potential than Mesa Laboratories, analysts believe Sono-Tek is more attractive than Mesa Laboratories.

Mesa Laboratories has a beta of 0.966, which suggesting that the stock is 3.358% less volatile than S&P 500. In comparison Sono-Tek has a beta of -0.016, suggesting its less volatile than the S&P 500 by 101.624%.

Mesa Laboratories has a quarterly dividend of $0.16 per share corresponding to a yield of 0.5%. Sono-Tek offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mesa Laboratories pays -1.36% of its earnings as a dividend. Sono-Tek pays out -- of its earnings as a dividend.

Mesa Laboratories quarterly revenues are $62.8M, which are larger than Sono-Tek quarterly revenues of $5.2M. Mesa Laboratories's net income of -$1.7M is lower than Sono-Tek's net income of $274.2K. Notably, Mesa Laboratories's price-to-earnings ratio is -- while Sono-Tek's PE ratio is 56.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mesa Laboratories is 2.90x versus 3.08x for Sono-Tek. Usually stocks with elevated PS ratios are considered overvalued.